Newron Pharmaceuticals SpA
SIX:NWRN

Watchlist Manager
Newron Pharmaceuticals SpA Logo
Newron Pharmaceuticals SpA
SIX:NWRN
Watchlist
Price: 7.2 CHF -1.1% Market Closed
Market Cap: 140.1m CHF
Have any thoughts about
Newron Pharmaceuticals SpA?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

-12.4
Current
-9.5
Median
13.3
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-12.4
=
Enterprise Value
171.1m CHF
/
EBITDA
-14.8m EUR
All Countries
Close

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
32.4
2-Years Forward
EV/EBITDA
92
3-Years Forward
EV/EBITDA
51.1

See Also

Discover More